Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a fully integrated American biotechnology company that invents, develops, manufactures, and commercializes antibody-based medicines for serious diseases, generating $14.3 billion in GAAP total revenue in fiscal 2025. Its most important products — EYLEA HD and EYLEA for retinal diseases, Dupixent for type 2 inflammatory conditions, and Libtayo for certain cancers — are built on proprietary drug-discovery platforms that have produced thirteen FDA-approved therapies over nearly four decades. The company is anchored by two of the longest-tenured founder-executives in the industry and a fortress balance sheet holding $17.8 billion in cash and marketable securities against $2.7 billion of debt.

This is a story about a barbell: on one end, a world-class immunology franchise in Dupixent that is putting up growth numbers most large-cap biotechs can only envy; on the other, an ophthalmology franchise in EYLEA that is entering what looks like the most consequential competitive transition in its history. Between them sits one of the broadest and most expensive R&D engines in the industry, spending nearly $6 billion a year in pursuit of the next act. The file turns on a single question: whether the Dupixent tailwind and the pipeline's output can outrun the EYLEA headwind fast enough to keep the earnings compounding that has defined this company for a decade.

Regeneron trades at roughly 17.6 times trailing GAAP earnings with a net cash position exceeding $15 billion — a multiple that embeds a healthy dose of skepticism about the sustainability of its current earnings power. Understanding whether that skepticism is warranted requires a close look at the three engines that drive this business: the EYLEA franchise, the Sanofi collaboration profit share, and an R&D organization that is among the most ambitious in the industry.